Equities

Amarin Corporation PLC

Amarin Corporation PLC

Actions
  • Price (EUR)4.14
  • Today's Change-0.01 / -0.24%
  • Shares traded550.00
  • 1 Year change-72.03%
  • Beta2.9834
Data delayed at least 15 minutes, as of Oct 30 2020 19:55 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

  • Revenue in USD (TTM)546.00m
  • Net income in USD-12.53m
  • Incorporated1989
  • Employees965.00
  • Location
    Amarin Corporation PLCGemini House, Bartholomews WalkDUBLIN FK7 9JQIrelandIRL
  • Phone+353 16699020
  • Websitehttp://www.amarincorp.com/
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.